ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan's Hisamitsu Pharmaceutical has offered to acquire Miami-based Noven Pharmaceuticals for $430 million. Both companies develop transdermal drug delivery systems, or patches, mostly focusing on women's health, central nervous system diseases, and pain relief. Hisamitsu already owns 5% of Noven and considers acquiring the firm a quick way to boost its U.S. presence. Employing 610 people, Noven recorded sales of $109 million in 2008. Hisamitsu mostly develops pain relief patches and skin treatments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter